We are live on ! Find out more
HP

Hikari Power Portfolio holdings

AUM $855M
1-Year Est. Return 14.24%
This Fund
S&P 500
This Quarter Est. Return
+2.3%
1 Year Est. Return
+14.24%
3 Year Est. Return
+53.45%
5 Year Est. Return
+75.51%
10 Year Est. Return
+220.8%
AUM
$741M
AUM Growth
+$38.7M
Cap. Flow
+$31.5M
Cap. Flow %
4.25%
Top 10 Hldgs %
60.64%
Holding
104
New
35
Increased
22
Reduced
3
Closed
10

Top Buys

Rank Stock Value
1
WAB icon
Wabtec
WAB
+$12.3M
2
WAT icon
Waters Corp
WAT
+$9M
3
DO
Diamond Offshore Drilling
DO
+$6.09M
4
GILD icon
Gilead Sciences
GILD
+$5.17M
5
RTX icon
RTX Corp
RTX
+$4.82M

Top Sells

Rank Stock Value
1
IBM icon
IBM
IBM
+$27.9M
2
CSCO icon
Cisco
CSCO
+$2.32M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$1.06M
4
UTHR icon
United Therapeutics
UTHR
+$1.05M
5
DBVT
DBV Technologies
DBVT
+$1.03M

Sector Composition

Rank Sector Weight
1 Financials 38.94%
2 Healthcare 24.52%
3 Industrials 11.96%
4 Technology 10.74%
5 Energy 5.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNCE
101
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
-11,743
Closed -$200K
TFCF
102
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
-29,100
Closed -$925K

Similar funds

Hikari Power's Q2 2017 Portfolio in Review

As of Q2 2017, Hikari Power held 104 positions worth $741M, up 5.5% from $703M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Hikari Power deployed $31.5M of net new capital in Q2 2017, opening 35 new positions and adding to 22 existing holdings. Its largest new stake was Waters Corp: 51,800 shares worth $9.52M.

By sector, the portfolio is most concentrated in Financials at 39% of assets, down from 40% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was IBM, an estimated $27.9M trimmed.

  • Hikari Power's largest Q2 2017 buy was Waters Corp: 51,800 shares worth $9.52M.
  • Hikari Power added most to Wabtec in Q2 2017, an estimated $12.3M increase.
  • Hikari Power's biggest Q2 2017 reduction was IBM, cutting an estimated $27.9M.
  • Hikari Power fully exited Ligand Pharmaceuticals in Q2 2017, selling an estimated $1.06M.
  • Hikari Power's ten largest holdings make up 61% of its $741M portfolio in Q2 2017.
  • Hikari Power opened 35 new positions and closed 10 in Q2 2017.
  • Hikari Power's portfolio value rose 5.5% quarter-over-quarter to $741M.

Based on Hikari Power's 13F filing for Q2 2017, filed 9 Aug 2017.